Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients based on induction chemotherapy response.

CONCLUSIONS: Tumor response to IC was an independent prognostic factor for patients with NPC. For the patients who achieved CR/PR after IC, patients receiving high CCD showed significantly improved 3-year PFS and DMFS compared with patients receiving low CCD. Balancing toxicity and efficacy, 200 mg/m2 seemed to be the optimal dose in the CR/PR groups. However, enhancement of CCD did not provide survival benefit for patients who achieved SD/PD after IC, and treatment options for these patients require further consideration. PMID: 31078941 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31078941?dopt=Abstract

Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - May 8, 2019 Category: Radiology Authors: Liu SL, Sun XS, Yan JJ, Chen QY, Lin HX, Wen YF, Guo SS, Liu LT, Xie HJ, Tang QN, Liang YJ, Li XY, Lin C, Du YY, Yang ZC, Xiao BB, Yang JH, Tang LQ, Guo L, Mai HQ Tags: Radiother Oncol Source Type: research